The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.

Autor: Eslami G; Abadan Faculty of Medical Sciences, Abadan, Iran., Mousaviasl S; Abadan Faculty of Medical Sciences, Abadan, Iran., Radmanesh E; Abadan Faculty of Medical Sciences, Abadan, Iran., Jelvay S; Abadan Faculty of Medical Sciences, Abadan, Iran., Bitaraf S; Department of Epidemiology, Tehran University of Medical Sciences, Tehran, Iran., Simmons B; Faculty of Medicine, Imperial College London, London, UK., Wentzel H; Faculty of Medicine, Imperial College London, London, UK., Hill A; Department of Translational Medicine, University of Liverpool, UK., Sadeghi A; Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute Tehran University of Medical Sciences, Tehran, Iran., Freeman J; Global Health New Zealand, New Zealand., Salmanzadeh S; Infectious and Tropical Diseases Research Centre, Ahwaz Jundishapur University of Medical Sciences, Ahwaz, Iran., Esmaeilian H; Abadan Faculty of Medical Sciences, Abadan, Iran., Mobarak M; Abadan Faculty of Medical Sciences, Abadan, Iran., Tabibi R; Abadan Faculty of Medical Sciences, Abadan, Iran., Jafari Kashi AH; Abadan Faculty of Medical Sciences, Abadan, Iran., Lotfi Z; Abadan Faculty of Medical Sciences, Abadan, Iran., Talebzadeh SM; Abadan Faculty of Medical Sciences, Abadan, Iran., Wickramatillake A; University of Moratuwa, Moratuwa, Sri Lanka., Momtazan M; Abadan Faculty of Medical Sciences, Abadan, Iran., Hajizadeh Farsani M; Abadan Faculty of Medical Sciences, Abadan, Iran., Marjani S; Abadan Faculty of Medical Sciences, Abadan, Iran., Mobarak S; Abadan Faculty of Medical Sciences, Abadan, Iran.

Publikováno v: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2020 Nov 01; Vol. 75 (11), pp. 3366-3372.